Skip to content

Neurological Emergency Utility and Resource Optimization in Triage

Health Technology Assessment (HTA) of point-of-care Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase L1(UCH-L1) biomarkers screening for optimizing triage of Traumatic Brain and Spinal Cord Injuries: A Cost-Effectiveness Study in Tertiary Care - NEURO-TRIAGE

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/12/098611
Enrollment
880
Registered
2025-12-08
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: S098- Other specified injuries of head

Interventions

Intervention1: Point of care based Triage: The biomarkers will be assessed through point of care machine and the triage will be done based on their results Control Intervention1: Imaging based CT and

Sponsors

Department of Health Research Ministry of Health and Family Welfare New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adults aged more than 18 years Patients presenting to the emergency department within 6 hours of suspected TBI or SCI Patients with Glasgow Coma Scale (GCS) score between 9 to 15 (mild to moderate TBI) or suspected acute SCI based on clinical presentation. Willingness to undergo rapid point-of-care GFAP and UCH-L1 screening. Informed written consent provided by the patient or legal guardian.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
sensitivity, specificity, AUCTimepoint: Time points is specific time at which the outcome will be assessed estimated at baseline, 4 weeks and 8 weeks

Secondary

MeasureTime frame
NilTimepoint: Nil

Countries

India

Contacts

Public ContactManish Singh

GSVM Medical College Kanpur

manishsinghneurosurgry@gmail.com9450996994

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026